AstraZeneca presented findings this week from its positive Phase III DAPA-HF trial of Farxiga (dapagliflozin) that may well be practice-changing in heart failure (HF) with reduced ejection fraction (HFrEF), while Novartis revealed detailed data from its less successful Phase III PARAGON-HF study of Entresto (sacubitril/valsartan) that the company argues nevertheless could be for the other half of the HF population with preserved ejection fraction (HFpEF).
To provide FirstWord readers with rapid feedback on if and how the two agents are likely to impact prescribing patterns, we are hosting an expert call with a key opinion leader (KOL) later this week.
Key topics that will be discussed during the call include, among other things… what were the biggest questions coming into this week’s DAPA-HF readout and how were they answered; will these data be practice-changing and, if so, how quickly; where will Farxiga fit into the treatment algorithm for HFrEF; will it result in less use of Entresto and how will physicians decide between the two; could you see the two drugs being used in combination; is this likely to be a class effect common to all SGLT2 inhibitors; how familiar are cardiologists with SGLT2 inhibitors and are the DAPA-HF results strong enough to raise the profile of the class; to what proportion of HFrEF patients do you expect SGLT2 inhibitors will be prescribed; how impressed are you by the 15% reduction in HF hospitalisations with no cardiovascular death benefit achieved by Entresto in PARAGON-HF; would you recommend approving it for HFpEF based on the totality of the dataset; if it is not approved, how much off-label use is Entresto likely to receive in HFpEF?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving HF treatment paradigm.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.